Will you offer cetuximab or panitumumab with FOLFOX in patients with metastatic left sided RAS/BRAF WT MSS colon cancer instead of bevacizumab?
Do the overall survival results of PARADIGM presented at ASCO 2022 change the standard of care?
Answer from: Medical Oncologist at Academic Institution
This is an important question and now we have two studies presented at ASCO attempting to address this. The GONO trial from Italy investigated FOLFIRI or FOLFOXIRI both with panitumumab showing no additional benefit of irinotecan. This was not confined to left-sided tumors but the RR was similar at ...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I expected this controversial question would come up! Obviously, it generates a lot of different responses among GI Med Oncs at this juncture. Apologies to Dr. Yoshino, whom I highly respect, but my personal take on the Phase III PARADIGM trial presented at ASCO AM 2022 is that it is not practice-ch...
Answer from: Medical Oncologist at Academic Institution
Based on the TRIPLETE study result, I would use FOLFOX/Panitumumab as first line treatment for patients with metastatic left side RAS/BRAF WT MSS colon cancer. However, instead of continuing with 5FU/panitumumab as a maintenance treatment (as used in the TRIPLETE study), would consider using intermi...
Answer from: Medical Oncologist at Academic Institution
The option of offering EGFR-AB in combination with chemotherapy has been and will remain a very reasonable choice in patients with RAS wild type and left sided colorectal cancers. PARADIGM study, presented in the plenary session of ASCO 2022, showed a survival benefit for use of FOLFOX/panitumumab v...